Tesla Unveils CyberCab and Robovan: A Bold Step Toward Autonomous Transportation, but Shares Tumble

At a highly anticipated event in Burbank, California, Elon Musk revealed Tesla’s (TSLA) latest innovation—the CyberCab, a fully autonomous, two-seat electric taxi designed to revolutionize urban transportation. With production slated for 2026 and a target price under $30,000, the CyberCab promises to make self-driving vehicles more accessible than ever. In addition to this sleek, futuristic… [Read More]

Symbotic (SYM) Puts Dinero in Investors Pockets on Announcement of Agreement with Walmex

PRISM NextGen Tech and AI Index company Symbotic Inc. (SYM), who is a leading provider of AI-powered robotics technology for the supply chain, announced today that it has entered into commercial agreements with Walmart de México y Centroamérica (MBV/BIVA: Walmex) to implement its cutting-edge warehouse automation systems at two of the retailer’s locations near Mexico… [Read More]

Stocks Dip From Record Highs Amid Warmer CPI, Cooler Jobs Data: Market Wrap

US stocks slipped from their recent highs as inflation data came in hotter than expected and jobless claims hit a yearly peak, raising concerns about the Federal Reserve’s next move. The core Consumer Price Index (CPI), which excludes volatile food and energy prices, rose 0.3% from August and 3.3% year-over-year, stalling some of the progress… [Read More]

On November 6th, 2024, Aditxt Acquisition Target, Appili Therapeutics Will Hold Meeting for Shareholders to Vote on Transaction

The innovative platform company Aditxt (ADTX) who is dedicated to accelerating promising health innovations has announced one of its acquisition targets, Appili Therapeutics (APLI) has begun disseminating company information as it related to their upcoming special meeting of shareholders which will be virtually held on November 6th, 2024. Applil’s board of directors recommend shareholders to… [Read More]

iBio and AstralBio Provide Update on Myostatin Program for Obesity: Lead Molecule Identified with Potential for Extended Half-Life and Subcutaneous Dosing

iBio (NYSEA: IBIO), a company leveraging AI for precision antibody immunotherapies, announced an update on its myostatin program targeting obesity and cardiometabolic diseases in collaboration with AstralBio. The two companies have identified a lead molecule with the potential to treat muscle wasting and obesity, designed for subcutaneous dosing and with an extended half-life. Leveraging iBio’s… [Read More]

NeuroSense Therapeutics Initiates Regulatory Submission for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics (NASDAQ: NRSN) has begun the regulatory process to seek early commercialization approval for its lead drug candidate, PrimeC, in Canada under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy. This follows positive Phase 2b trial results, where PrimeC demonstrated a 36% reduction in ALS disease progression and a 43% improvement in survival rates. NeuroSense… [Read More]

Counting Points Was So 90’s. Weight Watchers (WW) Soars Over 40% On Compounded GLP-1 Offering

WeightWatchers (WW) announced it will be adding compounded semaglutide to is offering. This will enhance the company’s holistic weight management program and provide its members to access to behavioral and clinical solutions with support from board-certified clinicians, registered dietitians, and the global WeightWatchers community. Approximately 45% of WeightWatchers Clinic members eligible for and prescribed a… [Read More]

Worksport Ltd. Expands EV Accessories Lineup with Tonneau Covers and Solar Power Options for Rivian R1T

Worksport Ltd. (NASDAQ: WKSP), a leader in hybrid and clean energy solutions for light trucks and consumer goods, is set to unveil its new aftermarket accessories tailored for the Rivian R1T electric pickup truck. Nearing the final stages of product engineering, Worksport’s premium tonneau covers will be compatible with the Rivian R1T, marking a key… [Read More]